WallStSmart

Ferrari NV (RACE)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ferrari NV generates 130% more annual revenue ($7.08B vs $3.07B). RACE leads profitability with a 22.6% profit margin vs 16.1%. WST appears more attractively valued with a PEG of 2.89. WST earns a higher WallStSmart Score of 55/100 (C-).

RACE

Buy

55

out of 100

Grade: C-

Growth: 6.0Profit: 9.0Value: 4.7Quality: 8.0
Piotroski: 4/9Altman Z: 2.81

WST

Buy

55

out of 100

Grade: C-

Growth: 4.7Profit: 8.0Value: 4.7Quality: 7.3
Piotroski: 5/9Altman Z: 4.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RACESignificantly Overvalued (-215.2%)

Margin of Safety

-215.2%

Fair Value

$121.49

Current Price

$322.02

$200.53 premium

UndervaluedFair: $121.49Overvalued
WSTSignificantly Overvalued (-257.4%)

Margin of Safety

-257.4%

Fair Value

$68.88

Current Price

$245.27

$176.39 premium

UndervaluedFair: $68.88Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RACE5 strengths · Avg: 8.8/10
Return on EquityProfitability
45.0%10/10

Every $100 of equity generates 45 in profit

Market CapQuality
$60.04B9/10

Large-cap with strong market position

Profit MarginProfitability
22.6%9/10

Keeps 23 of every $100 in revenue as profit

Operating MarginProfitability
28.3%8/10

Strong operational efficiency at 28.3%

Free Cash FlowQuality
$1.41B8/10

Generating 1.4B in free cash flow

WST2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.9110/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Areas to Watch

RACE4 concerns · Avg: 3.5/10
P/E RatioValuation
31.6x4/10

Premium valuation, high expectations priced in

Price/BookValuation
12.8x4/10

Trading at 12.8x book value

EPS GrowthGrowth
2.9%4/10

2.9% earnings growth

PEG RatioValuation
3.472/10

Expensive relative to growth rate

WST3 concerns · Avg: 3.3/10
P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
2.1%4/10

2.1% earnings growth

PEG RatioValuation
2.892/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : RACE

The strongest argument for RACE centers on Return on Equity, Market Cap, Profit Margin. Profitability is solid with margins at 22.6% and operating margin at 28.3%.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.

Bear Case : RACE

The primary concerns for RACE are P/E Ratio, Price/Book, EPS Growth.

Bear Case : WST

The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.

Key Dynamics to Monitor

WST carries more volatility with a beta of 1.18 — expect wider price swings.

WST is growing revenue faster at 7.5% — sustainability is the question.

RACE generates stronger free cash flow (1.4B), providing more financial flexibility.

Monitor AUTO MANUFACTURERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RACE scores higher overall (55/100 vs 55/100), backed by strong 22.6% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ferrari NV

CONSUMER CYCLICAL · AUTO MANUFACTURERS · USA

Ferrari NV designs, designs, produces and sells high performance sports cars. The company is headquartered in Maranello, Italy.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?